RADIATION THERAPY ONCOLOGY GROUP

这是继续参与放射治疗的申请 肿瘤学组的长期目标是提高肿瘤的性质和质量， 放射治疗是为患有各种癌症的病人提供的护理。 纽约大学打算加强其对RTOG的承诺， 耐心的积累和承担更大的领导作用。 我们计划 利用我们在癌症多模式管理方面的机构优势， 在选定的情况下研究化疗和放疗的组合。 纽约大学刚刚提出了一项研究顺铂疗效的试验 作为晚期头颈部患者放疗的辅助治疗 癌 我们计划提出类似的研究，利用潜在的 药物配合放疗提高治愈率 在癌症治疗的各个方面，如妇科恶性肿瘤， 脑转移 除了我们继续参与纽约 大学在治疗恶性肿瘤方面建立了国家领导地位 黑色素瘤应该允许我们成为最近 激活的协议，寻求定义最佳剂量分数， 治疗这种疾病。 大量的病人 晚期转移性疾病的病人送到贝尔维尤医院 我们是最近激活的治疗方案的主要贡献者， 骨转移 因此，有一个坚实的基础，期待积极的集团 在近期和遥远的未来参与。 此外，纽约大学打算开发一种基于微型计算机的通信系统， 集团内的网络。 这将提供连续、快速的交流 所有成员之间的想法，在一个全国性的成本的一小部分， 会议 此外，该网络还将为其他 合作团体。 纽约大学将有能力参与 几乎所有的组内试验。 耗资数百万美元的翻新工程 放射肿瘤学改进计划正在如期进行。 一 新的实验室，专门致力于研究恶性肿瘤的高温 疾病，最近已经完成，将有助于我们参与 在RTOG高温试验中。 同样，一个新的20 MV直线加速器 应该在1983年夏天投入使用，并提供更多光子， 电子处理能力。

This is an application to continue participation in the Radiation Therapy Oncology Group's long-term objective of improving the nature and quality of radiation therapy care for patients who suffer from various forms of cancer. NYU intends to intensify its commitment to the RTOG both in terms of patient accrual and in assuming a greater role of leadership. We plan to exploit our institutional strength in multimodality management of cancer to investigate chemotherapy-radiotherapy combinations in selected situations. NYU has just proposed a trial to investigate the efficacy of cis-platinum as an adjuvant to radiotherapy for patients having advanced head and neck cancer. We plan to propose similar studies, utilizing the potential enhancement of the therapeutic ratio by combining drugs with radiotherapy in such diverse aspects of cancer care as gynecologic malignancies and brain metastases. In addition to our continued participation New York University's established national leadership in the treatment of malignant melanoma should permit us to become a leading contributor to the recently activated protocol seeking to define the optimal dose fraction for treatment of this disease. The substantial number of patients that present with advanced metastatic disease to our Bellevue Hospital has already made us the leading contributor to the recently activated protocol for therapy of bone metastases. Thus, there is a firm basis to expect active group participation in the immediate and distant future. Furthermore, NYU intends to develop a micro-computer based communications network within the group. This will provide continuous, rapid interchange of ideas between all members at a fraction of the cost of a nationwide meeting. In addition, this network will provide a model for other cooperative groups. NYU will have the capability of participating in virtually all groupwide trials. A multimillion dollar renovation and improvement program in radiation oncology is progressing on schedule. A new laboratory, solely dedicated to the study of hyperthermia in malignant disease, recently has been completed and will facilitate our participation in RTOG hyperthermia trials. Similarly, a new 20 MV linear accelerator should be operational by summer 1983 and provide increased photon and electron treatment capability.